U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07810777) titled 'PRA-216 Atopic Dermatitis Safety and Efficacy Study' on Sept. 03.
Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: Active PRA-216
biologic
DRUG: Placebo
matching placebo for PRA-216
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Prana Therapies Inc
Published by HT Digital Content Services with permission from Health Daily Digest....